Every year in the world, more than 50M patients suffer from skin defects (e.g. burns, excision, etc.) and need surgical intervention to restore normal skin function. Standard of care, skin autografting, very often leaves these patients with permanent and disfiguring scars, which can also be painful and highly debilitating. Indeed, they may also impair movement and growth, and require several follow-up surgeries, intense homecare and psychosocial rehabilitation. Hence, scars significantly affect patient’s quality of life and pose an economic burden for the health-care system. Furthermore, in the case of large wounds, donor site shortage represents a real problem.

denovoSkin™ is a patented, personalized, bio-engineered human skin graft. It is engineered in large quantities starting off from a stamp-sized skin biopsy of the patient, thus solving the donor site shortage issue. Moreover, because of its dermo-epidermal structure, denovoSkin is expected to minimally scar after transplantation. Its outstanding performance could considerably reduce or even avoid further corrective interventions, allowing for considerable savings in terms of costs.